ArticleJournal of the National Cancer Center2026
Upper gastrointestinal cancers global burden profile, trends, contributors, and attributable change in life expectancy from 1990 to 2021.
Article in Journal of the National Cancer Center, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Upper gastrointestinal endoscopic screening uptake and associated factors in East Asia: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper gastrointestinal (GI) cancers, comprising esophageal cancer (EC) and gastric cancer (GC), remain a significant global health burden with disproportionate geographic distribution of incidence and mortality. A comprehensive assessment of global and regional patterns and trends of upper GI cancer burden is essential to inform targeted prevention strategies. Methods: Data were sourced from the Global Burden of Disease (GBD) study 2021. We examined the incidence, mortality, and life expectancy (LE) impacts of upper GI cancers from 1990 to 2021 across 21 GBD world regions. Trends were assessed using age-standardized rates and average annual percentage change (AAPC). Non-modifiable demographic factors and modifiable risk-attributable burdens were analyzed. A three-step decomposition method was applied to quantify the contribution of upper GI cancer to changes in LE. Results: In 2021, upper GI cancers accounted for 1.80 million new cases and 1.49 million deaths globally, with Asia contributing over 70% of the burden. Global age-standardized incidence and mortality rates for upper GI cancers declined from 1990 to 2021, with AAPC of -1.53% and -1.87%, respectively, although absolute incidence and deaths increased due to population growth and ageing, contributing to 1.13 million deaths for upper GI cancers. Population expansion and ageing drove increases in age-related deaths during the study period and were offset by reduced incidence and case fatality. Risk-attributable deaths declined for most modifiable factors, with tobacco remaining the leading risk, responsible for 21.9% of all deaths. A total of 0.24 year of LE gained was attributable to upper GI cancers from 1990 to 2021. Regionally, high-income Asia Pacific achieved the greatest gains in LE (0.67 years). GC predominantly contributed to the most gains, whereas EC mostly contributed to LE changes in Central and East Asia (0.27 years and 0.19 years, respectively). Conclusions: Although the burden of upper GI cancers has declined, progress is uneven, and the absolute burden remains high in Asia. Continued region-specific prevention, risk factor control, and equitable access to early detection and treatment are essential to further reduce the disease burden and close global disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.